CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 0
Operating expenses:
Research and development	473	643
Selling, general and administrative	522	1,253
Total operating expenses	995	1,896
Operating loss	(995)	(1,896)
Other income (expense):
Grant income	118	0
Change in fair value of warrant liability	3	(100)
Total other income (expense), net	121	(100)
Net loss	$ (874)	$ (1,996)
Basic and diluted net loss per share	$ (0.09)	$ (0.24)
Weighted-average common shares, basic and diluted	9,388	8,287